Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs

被引:35
|
作者
Lasorsa, Alessia [1 ]
Nardella, Maria I. [1 ]
Rosato, Antonio [1 ]
Mirabelli, Valentina [2 ]
Caliandro, Rosanna [3 ,4 ]
Caliandro, Rocco [2 ]
Natile, Giovanni [1 ]
Arnesano, Fabio [1 ]
机构
[1] Univ Bari Aldo Moro, Dept Chem, Via Orabona 4, I-70125 Bari, Italy
[2] CNR, Inst Crystallog, Via Amendola 122-O, I-70126 Bari, Italy
[3] Free Univ Bolzano, Fac Sci & Technol, Bioorgan Chem & Biocrystallog Lab B 2 Cl, Piazza Univ 5, I-39100 Bolzano, Italy
[4] CNR, Inst Crystallog, Area Sci Pk Basovizza, I-34149 Trieste, Italy
关键词
CHAPERONE ATOX1; CELLULAR PHARMACOLOGY; ENDOPLASMIC-RETICULUM; TRANSPORT MECHANISMS; BINDING DOMAINS; CISPLATIN; PROTEIN; ATPASES; OXALIPLATIN; SENSITIVITY;
D O I
10.1021/jacs.9b05550
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Copper (Cu) is required for maturation of cuproenzymes, cell proliferation, and angiogenesis, and its transport entails highly specific protein-protein interactions. In humans, the Cu chaperone Atoxl mediates Cu(I) delivery to P-type ATPases Atp7a and Atp7b (the Menkes and Wilson disease proteins, respectively), which are responsible for Cu release to the secretory pathway and excess Cu efflux. Cu(I) handover is believed to occur through the formation of three-coordinate intermediates where the metal ion is simultaneously linked to Atoxl and to a soluble domain of Cu-ATPases, both sharing a CxxC dithiol motif. The ultrahigh thermodynamic stability of chelating S-donor ligands secures the redox-active and potentially toxic Cu(I) ion, while their kinetic lability allows facile metal transfer. The same CxxC motifs can interact with and mediate the biological response to antitumor platinum drugs, which are among the most used chemotherapeutics. We show that cisplatin and an oxaliplatin analogue can specifically bind to the heterodimeric complex Atox1-Cu(I)-Mnk1 (Mnk1 is the first soluble domain of Atp7a), thus leading to a kinetically stable adduct that has been structurally characterized by solution NMR and X-ray crystallography. Of the two possible binding configurations of the Cu(I) ion in the cage made by the CxxC motifs of the two proteins, one (bidentate Atoxl and monodentate Mnk1) is less stable and more reactive toward cis-Pt(II) compounds, as shown by using mutated proteins. A Cu(I) ion can be retained at the Pt(II) coordination site but can be released to glutathione (a physiological thiol) or to other complexing agents. The Pt(II)-supported heterodimeric complex does not form if Zn(II) is used in place of Cu(I) and transplatin instead of cisplatin. The results indicate that Pt(II) drugs can specifically affect Cu(I) homeostasis by interfering with the rapid exchange of Cu(I) between Atoxl and Cu-ATPases with consequences on cancer cell viability and migration.
引用
收藏
页码:12109 / 12120
页数:12
相关论文
共 50 条
  • [1] Structural and mechanistic aspects of platinum anticancer agents
    Ahmad, Saeed
    Isab, Anvarhusein A.
    Ali, Saqib
    TRANSITION METAL CHEMISTRY, 2006, 31 (08) : 1003 - 1016
  • [2] Structural and mechanistic aspects of platinum anticancer agents
    Saeed Ahmad
    Anvarhusein A. Isab
    Saqib Ali
    Transition Metal Chemistry, 2006, 31 : 1003 - 1016
  • [3] A copper connection to the uptake of platinum anticancer drugs
    Nitiss, JL
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) : 13963 - 13965
  • [4] Structural and Mechanistic Studies of Anticancer Platinum Drugs: Uptake, Activation, and the Cellular Response to DNA Binding
    Dhar, Shanta
    Lippard, Stephen J.
    PLATINUM AND OTHER HEAVY METAL COMPOUNDS IN CANCER CHEMOTHERAPY: MOLECULAR MECHANISMS AND CLINICAL APPLICATIONS, 2009, : 135 - 147
  • [5] Interaction of Copper Trafficking Proteins with the Platinum Anticancer Drug Kiteplatin
    Barbanente, Alessandra
    Galliani, Angela
    Iacobazzi, Rosa Maria
    Lasorsa, Alessia
    Nardella, Maria Incoronata
    Pennetta, Antonio
    Margiotta, Nicola
    Arnesano, Fabio
    CHEMMEDCHEM, 2022, 17 (01)
  • [6] Platinum anticancer drugs: The mechanistic study and new drug design
    Liu, Yangzhong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2017, 254
  • [7] Structural and mechanistic basis for a new mode of glycosyltransferase inhibition
    Pesnot, Thomas
    Jorgensen, Rene
    Palcic, Monica M.
    Wagner, Gerd K.
    NATURE CHEMICAL BIOLOGY, 2010, 6 (05) : 321 - 323
  • [8] Mechanistic and structural basis for inhibition of thymidylate synthase ThyX
    Basta, Tamara
    Boum, Yap
    Briffotaux, Julien
    Becker, Hubert F.
    Lamarre-Jouenne, Isabelle
    Lambry, Jean-Christophe
    Skouloubris, Stephane
    Liebl, Ursula
    Graille, Marc
    van Tilbeurgh, Herman
    Myllykallio, Hannu
    OPEN BIOLOGY, 2012, 2
  • [9] Structural and mechanistic basis for a new mode of glycosyltransferase inhibition
    Thomas Pesnot
    Rene Jørgensen
    Monica M Palcic
    Gerd K Wagner
    Nature Chemical Biology, 2010, 6 : 321 - 323
  • [10] Structural studies of interactions between anticancer platinum drugs and DNA
    Yang, DZ
    Wang, AHJ
    PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY, 1996, 66 (01): : 81 - 111